MC
CRSP icon

Merlin Capital’s CRISPR Therapeutics CRSP Stock Holding History

Merlin Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$605K Sell
8,879
-46
-0.5% -$3.29K 1.81% 32
2023
Q4 		$559K Sell
8,925
-167
-2% -$9.23K 1.79% 33
2023
Q3 		$413K Buy
9,092
+290
+3% +$15K 1.54% 37
2023
Q2 		$494K Buy
8,802
+1,517
+21% +$86.1K 1.67% 35
2023
Q1 		$330K Buy
7,285
+476
+7% +$23.1K 1.2% 45
2022
Q4 		$277K Buy
6,809
+754
+12% +$40K 0.68% 63
2022
Q3 		$396K Buy
+6,055
New +$439K 0.92% 48

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Merlin Capital's CRSP Position: Q1 2024 in Review

Merlin Capital reduced its CRISPR Therapeutics (CRSP) stake by 0.52% in Q1 2024, selling an estimated $3.29K and leaving 8,879 shares worth $605K. The position accounts for 1.81% of the portfolio, ranked #32.

Merlin Capital first reported a position in CRSP in Q3 2022 and has held it in 7 quarters since. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Merlin Capital held 8,879 shares of CRISPR Therapeutics worth $605K as of Q1 2024.
  • Merlin Capital sold 46 CRISPR Therapeutics shares in Q1 2024, an estimated $3.29K.
  • CRISPR Therapeutics made up 1.81% of Merlin Capital's portfolio in Q1 2024, its #32 holding.
  • Merlin Capital first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Merlin Capital's 13F filing for Q1 2024, filed 13 May 2024.